Classification and treatment of WHO grade II/III gliomas have dramatically changed. Implementing molecular markers into the WHO classification raised discussions about the significance of grading and clinical trials showed overall survival (OS) benefits for combined radiochemotherapy. As molecularly stratified treatment data outside clinical trials are scarce, we conducted this retrospective study.
Description
A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy | SpringerLink
%0 Journal Article
%1 Steidl2021
%A Steidl, Eike
%A Filipski, Katharina
%A Zeiner, Pia S.
%A Wagner, Marlies
%A Fokas, Emmanouil
%A Forster, Marie-Therese
%A Ronellenfitsch, Michael W.
%A Divé, Iris
%A Steinbach, Joachim P.
%A Harter, Patrick N.
%A Bähr, Oliver
%D 2021
%J Journal of Cancer Research and Clinical Oncology
%K cancer-research fulltext glioma retrospective shouldread survival
%R 10.1007/s00432-021-03511-y
%T A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy
%U https://doi.org/10.1007/s00432-021-03511-y
%X Classification and treatment of WHO grade II/III gliomas have dramatically changed. Implementing molecular markers into the WHO classification raised discussions about the significance of grading and clinical trials showed overall survival (OS) benefits for combined radiochemotherapy. As molecularly stratified treatment data outside clinical trials are scarce, we conducted this retrospective study.
@article{Steidl2021,
abstract = {Classification and treatment of WHO grade II/III gliomas have dramatically changed. Implementing molecular markers into the WHO classification raised discussions about the significance of grading and clinical trials showed overall survival (OS) benefits for combined radiochemotherapy. As molecularly stratified treatment data outside clinical trials are scarce, we conducted this retrospective study.},
added-at = {2021-03-18T20:28:23.000+0100},
author = {Steidl, Eike and Filipski, Katharina and Zeiner, Pia S. and Wagner, Marlies and Fokas, Emmanouil and Forster, Marie-Therese and Ronellenfitsch, Michael W. and Div{\'e}, Iris and Steinbach, Joachim P. and Harter, Patrick N. and B{\"a}hr, Oliver},
biburl = {https://www.bibsonomy.org/bibtex/260bbede17abc5fab5ab335bb23a7700c/marcsaric},
day = 04,
description = {A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy | SpringerLink},
doi = {10.1007/s00432-021-03511-y},
interhash = {1f3124ce4581d3b82143bad46197c0b5},
intrahash = {60bbede17abc5fab5ab335bb23a7700c},
issn = {1432-1335},
journal = {Journal of Cancer Research and Clinical Oncology},
keywords = {cancer-research fulltext glioma retrospective shouldread survival},
month = feb,
timestamp = {2021-03-18T20:28:23.000+0100},
title = {A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy},
url = {https://doi.org/10.1007/s00432-021-03511-y},
year = 2021
}